From: EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy
BC subtype | EVI1 | pCR (ypT0 ypN0) | DFS | OS | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Odds ratio (95% CI) | p-value* | Int. p-value | Hazard ratio (95% CI) | p-value* | Int. p-value | Hazard ratio (95% CI) | p-value* | Int. p-value | ||
HR + /HER2- | continuous | 1.18 (0.56–2.50) | 0.666 | 0.555 | 1.11 (0.73–1.70) | 0.617 | 0.140 | 1.00 (0.59–1.69) | 0.988 | 0.304 |
HR + /HER2 + | continuous | 0.81 (0.32–2.05) | 0.662 | 0.87 (0.52–1.45) | 0.581 | 0.76 (0.40–1.46) | 0.411 | |||
HR-/HER2 + | continuous | 1.52 (0.53–4.41) | 0.440 | 0.81 (0.40–1.65) | 0.562 | 0.62 (0.29–1.34) | 0.226 | |||
TNBC | continuous | 1.41 (0.79–2.52) | 0.249 | 0.75 (0.50–1.13) | 0.165 | 0.74 (0.47–1.18) | 0.204 | |||
HR + /HER2- | EVI1 high vs low | 1.01 (0.51–2.01) | 0.968 | 0.283 | 1.01 (0.69–1.48) | 0.961 | 0.274 | 1.00 (0.61–1.64) | 0.992 | 0.290 |
HR + /HER2 + | EVI1 high vs low | 0.96 (0.33–2.75) | 0.376 | 0.98 (0.54–1.79) | 0.960 | 0.81 (0.37–1.78) | 0.602 | |||
HR-/HER2 + | EVI1 high vs low | 1.32 (0.52–3.35) | 0.566 | 0.93 (0.46–1.91) | 0.849 | 0.67 (0.27–1.63) | 0.370 | |||
TNBC | EVI1 high vs low | 1.60 (0.90–2.85) | 0.110 | 0.77 (0.48–1.23) | 0.271 | 0.76 (0.44–1.31) | 0.314 |